Journal of Pharmacogenomics & Pharmacoproteomics

Population-level pharmacogenomics for precision drug development in dementia

Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions

Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer's disease and related risk factors

Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease

Gene interactions in the pharmacogenomics of Alzheimer's disease

Can cloud-based tools accelerate Alzheimer's disease drug discovery?

Pharmacogenetics of vascular risk factors in Alzheimer's disease

Genetic variants specific to aging-related verbal memory: Insights from GWASs in a population-based cohort

Pharmacogenomics of Alzheimer's and Parkinson's diseases

Opportunities in pharmacogenomics for the treatment of Alzheimer's disease

Sirtuins in alzheimer's disease: SIRT2-related genophenotypes and implications for pharmacoepigenetics

The role of pharmacogenomics in adverse drug reactions

Pharmacogenetic considerations in the treatment of Alzheimer's disease

The broad impact of TOM40 on neurodegenerative diseases in aging

Spectrum of neuromuscular disorders with hyperCKemia from a tertiary care pediatric neuromuscular center

Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia

Persistent asymptomatic or mild symptomatic hyperCKemia due to mutations in ANO5: the mildest end of the anoctaminopathies spectrum

Calpainopathy as differential diagnosis of idiopathic hyperCKemia

Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia

Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort